Buchumschlag

586 | OBINUTUZUMAB COMBINED WITH BENDAMUSTINE IN THE TREATMENT OF MATURE B‐CELL LYMPHOMA: AN OPEN‐LABEL, MULTICENTER STUDY

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Y. Yan, X. Hu, X. Sun, X. Xiang, Y. Wang, T. Wang, K. Zhang, L. Wang, Y. Jia, C. Gui, Y. Yu, R. Lyu, W. Xiong, S. Deng, W. Liu, L. Huang, G. An, L. Qiu, S. Yi
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Hematological Oncology
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

607 | EFFICACY AND SAFETY OF ZANUBRUTINIB COMBINED WITH BENDAMUSTINE AND RITUXIMAB AS FIRST‐LINE TREATMENT FOR MANTLE CELL LYMPHOMA
von: H. Zhu, et al.
Veröffentlicht: (2025)

674 | CLINICOPATHOLOGICAL CHARACTERISTICS, TREATMENT RESPONSE, AND PROGNOSTIC FACTORS OF PATIENTS WITH INTRAVASCULAR LARGE B CELL LYMPHOMA: A MULTICENTER STUDY IN CHINA
von: Y. Guo, et al.
Veröffentlicht: (2025)

594 | MULTICENTER RETROSPECTIVE COHORT STUDY OF 805 PATIENTS WITH OCULAR ADNEXAL MARGINAL ZONE B‐CELL LYMPHOMA ON BEHALF OF THE CHINESE OCULAR LYMPHOMA COLLABORATIVE GROUP
von: X. Li, et al.
Veröffentlicht: (2025)

824 | R‐CHOP WITH SINTILIZUMAB IN FIRST‐LINE TREATMENT OF LARGE B‐CELL LYMPHOMA PATIENTS WITH TP53 MUTATIONS AND PD‐L1 EXPRESSION: A RANDOMIZED, MULTICENTER CLINICAL STUDY
von: Y. Che, et al.
Veröffentlicht: (2025)

317 | MOLECULAR SUBTYPE‐GUIDED R‐MINE+X REGIMEN IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: A SINGLE‐ARM, OPEN‐LABEL, MULTICENTER PHASE II STUDY
von: J. Liang, et al.
Veröffentlicht: (2025)

547 | A PROSPECTIVE MULTICENTER STUDY OF FCR ALTERNATING WITH IBRUTINIB IN TREATMENT‐NAIVE PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
von: T. Wang, et al.
Veröffentlicht: (2025)

750 | GOLIDOCITINIB MONOTHERAPY IN THE TREATMENT OF REFRACTORY/RELAPSED INDOLENT T/NK‐CELL LYMPHOMA: PRELIMINARY RESULTS FROM T‐LGLL COHORT
von: Y. Yu, et al.
Veröffentlicht: (2025)

756 | REAL‐WORLD STUDY OF GOLIDOCITINIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY PERIPHERAL T CELL LYMPHOMA: RETROSPECTIVE DATA FROM MEDICAL CENTERS IN CHINA
von: H. Huang, et al.
Veröffentlicht: (2025)

255 | THE EFFICACY, SAFETY AND RATIONALITY OF ORELABRUTINIB PLUS OBINUTUZUMAB (O2) IN SYSTEMIC TREATMENT‐NAÏVE MARGINAL ZONE LYMPHOMA: A PROSPECTIVE COHORT STUDY
von: J. Xu, et al.
Veröffentlicht: (2025)

638 | IMPACT OF FIRST‐LINE SETTING MAINTENANCE THERAPY ON PROGNOSIS IN DIFFUSE LARGE B‐CELL LYMPHOMA: A MULTICENTER RETROSPECTIVE STUDY
von: L. Lyu, et al.
Veröffentlicht: (2025)

165 | LINPERLISIB PLUS CHOP FOR NEWLY DIAGNOSED PERIPHERAL T‐CELL LYMPHOMA: A SINGLE‐ARM, OPEN‐LABLE, MULTI‐CENTER PHASE IB/II STUDY (LINCH TRIAL)
von: Q. Cai, et al.
Veröffentlicht: (2025)

628 | TREATMENT‐RELATED INFECTIONS AND CLINICAL OUTCOMES OF DIFFUSE LARGE B‐CELL LYMPHOMA TREATED WITH POLATUZUMAB VEDOTIN‐BASED COMBINATION THERAPY
von: N. Wang, et al.
Veröffentlicht: (2025)

601 | TARGETING NAMPT AND BTK IN MANTLE CELL LYMPHOMA: TP53‐DEPENDENT SYNERGISTIC THERAPY
von: Y. Liu, et al.
Veröffentlicht: (2025)

589 | THE EFFICACY AND SAFETY OF ORELABRUTINIB‐BASED REGIMENS IN THE TREATMENT OF MARGINAL ZONE LYMPHOMA: A RETROSPECTIVE REAL‐WORLD STUDY
von: H. Li, et al.
Veröffentlicht: (2025)

675 | A COMBINED EASIX‐IPI SCORE IMPROVES THE PROGNOSTIC STRATIFICATION OF NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA
von: J. Y. Tan, et al.
Veröffentlicht: (2025)

748 | EFFECTIVENESS AND SAFETY OF LINPERLISIB IN PATIENTS WITH MATURE T/NK‐CELL LYMPHOMA: A REAL‐WORLD RETROSPECTIVE STUDY
von: Z. Li, et al.
Veröffentlicht: (2025)

718 | AGGRESSIVE CLINICAL FEATURES AND POOR OUTCOME MAY ASSOCIATE WITH DECREASED IMMUNE FUNCTION IN HIV POSITIVE HL IN THE cART ERA: A MULTICENTER STUDY FROM CHINA
von: C. Wang, et al.
Veröffentlicht: (2025)

798 | PROTEOLYSIS‐TARGETING CHIMERA TARGETING BTK DEGRADATION FOR CANCER THERAPY IN MANTLE CELL LYMPHOMA
von: X. Wang, et al.
Veröffentlicht: (2025)

644 | EFFICACY OF ZANUBRUTINIB IN NEWLY DIAGNOSED MYD88‐MUTATED DIFFUSE LARGE B‐CELL LYMPHOMA: A RETROSPECTIVE SINGLE‐CENTER REAL‐WORLD STUDY
von: W. Huang, et al.
Veröffentlicht: (2025)

621 | EFFICACY AND SAFETY OF GLOFITAMAB COMBINED WITH TISLELIZUMAB IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: A PILOT STUDY IN CHINA
von: D. Zhou, et al.
Veröffentlicht: (2025)

758 | CLINICAL OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEPATOSPLENIC T‐CELL LYMPHOMA
von: Z. Zhang, et al.
Veröffentlicht: (2025)

284 | NOVEL ZCR (ZANUBRUTINIB, CHIDAMIDE, RITUXIMAB) ± CHOP REGIMEN DEMONSTRATES PROMISING EFFICACY IN FRONTLINE TREATMENT OF DOUBLE‐EXPRESSOR DIFFUSE LARGE B‐CELL LYMPHOMA
von: Z. Li, et al.
Veröffentlicht: (2025)

347 | ANTI‐PD‐1 ANTIBODY (TISLELIZUMAB) COMBINED WITH R‐CHOP FOR THE TREATMENT OF PREVIOUSLY UNTREATED PRIMARY MEDIASTINAL B‐CELL LYMPHOMA: A PROSPECTIVE PHASE II STUDY
von: W. Shu juan, et al.
Veröffentlicht: (2025)

587 | PHASE II STUDY OF ORELABRUTINIB PLUS OBINUTUZUMAB WITH OR WITHOUT CHEMOTHERAPY FOR MARGINAL ZONE LYMPHOMA PATIENTS WITH HIGH‐RISK RECURRENCE FACTORS
von: M. Hu, et al.
Veröffentlicht: (2025)

764 | REAL‐WORLD OUTCOMES OF MITOXANTRONE HYDROCHLORIDE LIPOSOME REGIMEN FOR PERIPHERAL T‐CELL LYMPHOMA: THE EFFICACY AND SAFETY ANALYSIS OF TREATMENT‐NAÏVE POPULATION
von: D. Zhao, et al.
Veröffentlicht: (2025)

881 | EPIDEMIOLOGY, TREATMENT PATTERN AND SURVIVAL OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION‐ASSOCIATED LYMPHOMA IN CHINA
von: C. Wang, et al.
Veröffentlicht: (2025)

UCLI03 | T‐CELL LYMPHOMA TREATMENT: THE CHINESE PERSPECTIVE
von: M. Wu, et al.
Veröffentlicht: (2025)

36 | FREQUENCY OF FUSION GENES AND THEIR CLINICAL IMPACTS IN CHINESE PEDIATRIC PATIENTS WITH T‐CELL LYMPHOBLASTIC LYMPHOMA
von: Y. Li, et al.
Veröffentlicht: (2025)

721 | TISLELIZUMAB COMBINED WITH CPEL (CHIDAMIDE, PREDNISONE, ETOPOSIDE, LENALIDOMIDE) FOLLOWED AUTOLOGOUS STEM CELL TRANSPLANT IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA
von: Y. Wang, et al.
Veröffentlicht: (2025)

403 | A SINGLE‐ARM, MULTI‐CENTER, OBSERVATIONAL STUDY OF SELINEXOR COMBINED BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE IN HIGH‐RISK NEWLY DIAGNOSED MULTIPLE MYELOMA
von: J. Yin, et al.
Veröffentlicht: (2025)

597 | ORELABRUTINIB COMBINED WITH ANTI‐CD20 MONOCLONAL ANTIBODIES IS HIGHLY EFFECTIVE AND WELL TOLERATED AS FIRST‐LINE THERAPY FOR MARGINAL ZONE B CELL LYMPHOMA
von: L. Wang, et al.
Veröffentlicht: (2025)

865 | THE IMPACT OF RADIOTHERAPY ON SURVIVAL IN YOUNGER PATIENTS WITH ADVANCED AGGRESSIVE B‐CELL LYMPHOMA IN THE RITUXIMAB ERA: A MULTI‐CENTER RETROSPECTIVE ANALYSIS
von: L. Wang, et al.
Veröffentlicht: (2025)

484 | SINGLE‐CELL ANALYSIS OF CIRCULATING IMMUNE HETEROGENEITY IN DIFFUSE LARGE B‐CELL LYMPHOMA HIGHLIGHTS DISTINCT IMMUNE CELL SIGNATURES IN IMMUNOTHERAPY
von: S. Zhang, et al.
Veröffentlicht: (2025)

476 | SPATIAL TRANSCRIPTOMICS IDENTIFIES PROGNOSTIC LYZ+ FIBROBLASTS AND THEIR COLOCALIZATION WITH FN1+ MACROPHAGES IN DIFFUSE LARGE B‐CELL LYMPHOMA
von: L. Dai, et al.
Veröffentlicht: (2025)

631 | EFFICACY OF POLA‐R‐CHP IN PREVIOUSLY UNTREATED CD5‐POSITIVE DIFFUSE LARGE B‐CELL LYMPHOMA
von: J. Sui, et al.
Veröffentlicht: (2025)

765 | COMBINATION OF LIPOSOMAL MITOXANTRONE WITH CYCLOPHOSPHAMIDE, VINCRISTINE, AND PREDNISONE (CMOP) IN TREATMENT‐NAÏVE PTCLs: A MULTICENTER, SINGLE‐ARM, PHASE Ib STUDY
von: H. Huang, et al.
Veröffentlicht: (2025)

768 | EFFICACY AND SAFETY OF SELINEXOR‐MELPHALAN COMBINED CONDITIONING REGIMEN FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
von: S. Su, et al.
Veröffentlicht: (2025)

817 | ADVANTIG‐101: A PHASE 1B/2 STUDY OF OCIPERLIMAB (ANTI‐TIGIT) PLUS TISLELIZUMAB (ANTI‐PD‐1) OR RITUXIMAB IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
von: Q. Cai, et al.
Veröffentlicht: (2025)

61 | A PIVOTAL STUDY OF SHR2554, AN ORAL INHIBITOR AGAINST ENHANCER OF ZESTE HOMOLOG 2 (EZH2), IN RELAPSED OR REFRACTORY (R/R) PERIPHERAL T‐CELL LYMPHOMA (PTCL)
von: Y. Song, et al.
Veröffentlicht: (2025)

136 | MINIMAL RESIDUAL DISEASE WITH BENDAMUSTINE‐RITUXIMAB WITH OR WITHOUT ACALABRUTINIB IN PATIENTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA: RESULTS FROM THE ECHO TRIAL
von: P. L. Zinzani, et al.
Veröffentlicht: (2025)